Convidencia’s injectable version was granted World Health Organization (WHO) Emergency Use Listing (EUL), and its inhalant counterpart, currently in phase three clinical trials, has shown enormous promise.
“We’re bringing a solution, which is needle-free (so no pain at the point of injection), no swelling, and it’s extremely well-tolerated locally. We hope that by bringing something more end-user-friendly, there will be an incentive for people to consider it as a booster,” Morgon states.
